Institute of Cancer Research, United Kingdom
icr.ac.ukLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
111
Active
39
Phase 3
19
Total enrollment
105,762
Pipeline matrix
Showing 39 of 39 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Paclitaxel | — | — | — | — | — | 1 | |
| Ifosfamide | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| Abemaciclib | — | — | — | — | — | 1 | |
| Endocrine therapy | — | — | — | — | — | 1 | |
| Aromatase Inhibitors | — | — | — | — | — | 1 | |
| Temozolomide | — | — | — | — | 3 | ||
| Olaparib | — | — | — | — | — | 4 | |
| Defactinib | — | — | — | — | 2 | ||
| Durvalumab | — | — | — | — | — | 2 | |
| Carboplatin | — | — | — | — | 2 | ||
| Hydrogen Peroxide | — | — | — | — | — | 2 | |
| AZD6738 | — | — | — | — | — | 2 | |
| Enzalutamide 40mg | — | — | — | — | — | 1 | |
| Amoxicillin 500mg | — | — | — | — | — | 1 | |
| Metronidazole 400mg | — | — | — | — | — | 1 | |
| Vancomycin 125mg | — | — | — | — | — | 1 | |
| Ciprofloxacin 500g | — | — | — | — | — | 1 | |
| Paxalisib | — | — | — | — | — | 1 | |
| ipatasertib | — | — | — | — | — | 1 | |
| Atezolizumab | — | — | — | — | — | 1 | |
| Avutometinib | — | — | — | — | — | 1 | |
| Niraparib oral | — | — | — | — | — | 1 | |
| SX-682 | — | — | — | — | — | 1 | |
| Apalutamide | — | — | — | — | — | 1 | |
| Ceralasertib | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | 4 | ||
| Tepotinib | — | — | — | — | — | 1 | |
| Dose Level 2 | — | — | — | — | — | 1 | |
| Dose Level 1 | — | — | — | — | — | 1 | |
| Dose Level -1 | — | — | — | — | — | 1 | |
| Dose Level 3 | — | — | — | — | — | 1 | |
| Maximum Tolerated Dose | — | — | — | — | — | 1 | |
| ASTX660 | — | — | — | — | — | 1 | |
| Amivantamab | — | — | — | — | — | 1 | |
| VS-6766 | — | — | — | — | — | 1 | |
| Genetic SNP profiling | — | — | — | — | — | 2 | |
| Prostate cancer risk gene panel | — | — | — | — | — | 1 | |
| The i4i PRODICT® test. | — | — | — | — | — | 1 |
Next readouts
- 2018-04-14
- 2023-04-30
- 2024-04
- 2024-04-01
- 2026-03
- 2026-03-05
- 2026-06-30
- 2026-08
- 2026-12
- 2026-12
Top conditions
- Breast Cancer20
- Prostate Cancer18
- Cancer12
- Bladder Cancer5
- Adenocarcinoma of the Prostate3
- Malignant Primary Gliomas3
- Glioblastoma Multiforme (GBM)3
- Triple Negative Breast Cancer3
Frequently asked questions about Institute of Cancer Research, United Kingdom
- How many clinical trials does Institute of Cancer Research, United Kingdom have on ClinicalTrials.gov?
- Institute of Cancer Research, United Kingdom is listed as the lead sponsor on 111 clinical trials in ClinicalTrials.gov, 39 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Institute of Cancer Research, United Kingdom's trials are in Phase 3?
- 19 of Institute of Cancer Research, United Kingdom's trials are in Phase 3, spread across 39 active drug programs.
- What therapeutic areas does Institute of Cancer Research, United Kingdom focus on?
- Institute of Cancer Research, United Kingdom's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Prostate Cancer, Cancer, Bladder Cancer, Adenocarcinoma of the Prostate.
- When are Institute of Cancer Research, United Kingdom's next clinical trial readouts?
- Institute of Cancer Research, United Kingdom has 10 upcoming primary-completion readouts tracked here; the soonest is “The BARCODE 1 Pilot Study”, expected around 2018-04-14.